Key result
Low-dose DOAC thromboprophylaxis for 6 months was cost-effective for preventing VTE in intermediate-to-high risk cancer patients, with an ICER of $11,947 per QALY gained.
Why the study?
Randomized controlled trials have demonstrated that low-dose DOACs may reduce cancer-associated VTE, but their cost-effectiveness was not established.
Is low-dose DOAC thromboprophylaxis cost-effective compared to placebo for the prevention of VTE in patients with cancer at intermediate-to-high risk?
Population
Patients with cancer at intermediate-to-high risk for VTE
Comparison
Low-dose DOAC thromboprophylaxis for 6 months vs placebo
Design
Cost-utility analysis using a Markov state-transition model
Follow-up
Lifetime horizon
Authors
Loading...
May support low-dose DOAC use in intermediate-high risk cancer; leaves open need for randomized confirmation.
Is low-dose DOAC thromboprophylaxis cost-effective compared to placebo for the prevention of VTE in patients with cancer at intermediate-to-high risk?
Effect estimate: ICER $11,947
Low-dose DOAC thromboprophylaxis for 6 months is a highly cost-effective strategy for preventing VTE in cancer patients at intermediate-to-high risk, particularly those with a Khorana score ≥3.
Li et al. (2020) studied Cancer at intermediate-to-high risk for VTE. Low-dose direct oral anticoagulant (DOAC) vs. placebo was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER $11,947). Low-dose DOAC thromboprophylaxis for 6 months was cost-effective for preventing VTE in intermediate-to-high risk cancer patients, with an ICER of $11,947 per QALY gained.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: